Membership of the Royal Colleges of Physicians of the United Kingdom

OMass Therapeutics Expands Leadership Team with Two New Appointments

Retrieved on: 
Wednesday, August 2, 2023

Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.

Key Points: 
  • Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.
  • “Both Peter and Julia have a huge amount of experience in taking programs from preclinical through to clinical development and I am hugely excited about what they will bring to the OMass team,” said Ros Deegan, CEO of OMass Therapeutics.
  • “With our solid financial backing and new expanded facilities, we are growing our team strategically as we advance our pipeline of exciting early-stage assets in immunology and rare diseases.
  • In her most recent role at Kalvista Pharmaceuticals, she was responsible for strategy, leadership, recruitment and management of the non-clinical safety assessment team, leading toxicology, safety pharmacology and DMPK functions.

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.

Key Points: 
  • Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company's clinical development, regulatory and medical affairs teams.
  • Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys.
  • As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3.
  • Dr. Thomas Sciascia, MD, the co-founder of Trevi Therapeutics, previously served as Trevi's Chief Medical Officer and will be transitioning to Chief Science Officer.

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 24, 2022

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Edwin (Ed) Tucker, M.D., as Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Edwin (Ed) Tucker, M.D., as Chief Medical Officer (CMO), effective immediately.
  • Dr. Tucker brings to Goldfinch Bio over 30 years of clinical experience across a variety of therapeutic areas and early- and late-stage companies.
  • His deep expertise across clinical development and related functions makes him a tremendous and timely addition to our team, said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio.
  • Dr. Tucker joins Goldfinch Bio from Mirum Pharmaceuticals, where he served as Chief Medical Officer.